Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Tuesday delivered a sharp reminder that regulatory reality outranks clinical ambition. Bicycle Therapeutics cut 30% of its workforce and shelved its Nectin-4 drug conjugate—positioned as
The pharma GPU arms race went vertical at NVIDIA GTC 2026. Roche announced 2,176 new Blackwell GPUs—bringing its total footprint to more than 3,500 chips—claiming
The weekend edition captures a biotech landscape at multiple inflection points. Sana Biotechnology reported 14-month follow-up from its first-in-human hypoimmune islet cell transplant at ATTD
Eli Lilly escalated its war on the GLP-1 compounding ecosystem Thursday with a public safety warning that could permanently reshape the regulatory landscape: tirzepatide mixed
Thursday’s headlines underscore a biotech sector caught between transformative clinical milestones and escalating operational risks. BridgeBio delivered highly anticipated Phase 3 FORTIFY data for its
The FDA has set a radical regulatory precedent for ultra-rare diseases by approving leucovorin for a specific cerebral folate deficiency (CFD) subset without a clinical
Today delivered a rare alignment of clinical, regulatory, and scientific milestones. Xenon’s azetukalner posted the highest placebo-adjusted seizure reduction ever seen in a pivotal epilepsy
The 2026 MDA Clinical & Scientific Conference kicks off today in Orlando, serving as the first real-world test of the Makary-era regulatory posture on gene
Johnson & Johnson’s teclistamab combination secured a record-breaking 55-day FDA approval under the Commissioner’s National Priority Voucher pilot, setting a new benchmark for accelerated hematology
Manufacturing and regulatory milestones anchor today’s action. Vericel’s FDA approval for its new cell therapy facility positions MACI for international expansion, while Glenmark secures 180-day
